PAK6 and chronic myelogenous leukemia, BCR-ABL1 positive: We have recently identified p21-activated kinase 6 (PAK6) as a target gene of miR-185, a microRNA suppressed in TKI-resistant stem/progenitor cells, which is also a predictive biomarker for TKI response in CML patients treated with imatinib (IM) or nilotinib [9,10,11,12].